Solid-Phase vs. Liquid-Phase Peptide Synthesis: A Comparative Overview
In 2026, solid-phase methods account for an estimated 74.42 percent of the global peptide synthesis technology segment, according to market analysis from Precedence Research, while liquid-phase methods retained roughly 46.2 percent share of large-scale commercial manufacturing volume in 2025. The apparent contradiction reflects two different peptide economies operating side by side.
Market Context: Two Growth Curves, One Underlying Demand Shock
Fact.MR projects the peptide synthesis market at roughly USD 1.1 billion in 2026, growing to USD 2.4 billion by 2036 at a 7.9 percent compound annual growth rate. North America held an estimated 48.59 percent share of the peptide synthesis market in 2025. CordenPharma announced a three-year, EUR 900 million investment plan in mid-2024 to expand its peptide manufacturing platform, explicitly citing GLP-1 API demand as the driver.
The Core Chemical Distinction
SPPS, introduced by Bruce Merrifield in the 1960s, anchors the growing peptide chain to an insoluble polymer resin bead, with excess reagents simply rinsed away between steps. LPPS predates SPPS and builds the peptide chain entirely in solution, with intermediate products isolated and purified after each coupling.
Scalability and Automation
Standard Fmoc-based SPPS coupling cycles typically require 60 to 100 minutes per amino acid residue under conventional conditions. Microwave-assisted SPPS systems compress that to roughly 20 minutes per residue, and continuous-flow SPPS platforms have been reported to incorporate a residue in under 10 minutes manually. Snapdragon Chemistry introduced a liquid-phase process in September 2024 built on conventional API batch reactors combined with continuous-flow segments.
Sequence Length and Structural Considerations
SPPS handles complex, longer sequences well because each residue is added and purified as part of the same repeatable cycle. LPPS is comparatively better suited to shorter peptide chains, typically a few to roughly a dozen residues, where intermediates remain soluble and separable enough to purify economically.
Purity, Yield, and Analytical Outcomes
SPPS accumulates deletion sequences and truncation products across the synthesis cycle, typically removed at the final cleavage and purification step. LPPS purifies at intermediate stages, so impurities generally do not compound the way they can in SPPS, but each intermediate purification step introduces its own yield loss.
How It Works in Practice
Research suppliers working with longer or structurally complex sequences generally rely on solid-phase synthesis and its automated coupling cycles. Bluum Peptides, a research-use-only peptide supplier, sources its catalog from peptides produced via these modern automated solid-phase synthesis methods.
Trends Shaping the Next Phase of Peptide Synthesis
Capacity investment remains concentrated in liquid-phase and hybrid batch-flow processes. Flow chemistry is narrowing the automation gap for both methods, and overall peptide therapeutics market growth is pulling both synthesis methods along with it.
Conclusion
SPPS wins on flexibility, sequence complexity tolerance, and small-batch automation, which is why it dominates research-scale and custom peptide production. LPPS wins on cost-per-gram and infrastructure compatibility at multi-kilogram and multi-ton scale.
This article is intended for research and informational purposes only and does not constitute guidance for human use, diagnostic application, or therapeutic administration of any peptide compound.
